Featured Research

from universities, journals, and other organizations

New Rheumatoid Arthritis Drugs Work Better Than Standard Anti-inflammatories, Study Suggests

Date:
April 28, 2008
Source:
BMC Musculoskeletal Disorders
Summary:
The latest class of drugs used to treat rheumatoid arthritis are better than standard anti-inflammatories, according to a new study. Analysis of the combined results of thirteen trials showed that anti-TNF± drugs, given at recommended doses, were better than the usual treatments, such as methotrexate, for treating RA. Patients who had previously seen little benefit from methotrexate alone showed a better response with combined anti-TNF± plus methotrexate therapy.

A new study suggests that the latest class of drugs used to treat rheumatoid arthritis (RA) are better than standard anti-inflammatories.

RA is a chronic, debilitating, inflammatory disease of the joints, which is usually treated with anti-inflammatory drugs such as methotrexate or steroids. However, the discovery that a protein from white blood cells, known as tumour necrosis factor alpha (TNF±), caused some of the symptoms of RA, led to the development of novel drugs which block TNF±. This group of drugs, known as anti-TNF± drugs (which include infliximab, etanercept and adalimumab), are now commonly used to treat RA.

However, there have been no 'head-to-head' comparisons of the new anti-TNF± drugs in terms of safety or efficacy for the treatment of RA.

Alberto Alonso-Ruiz of the Cruces Hospital in Barakaldo, Vizcaya, Spain and colleagues at the Donostia Hospital and the University of the Basque Country, systematically searched for research on the use of anti-TNF± drugs in RA patients. They found thirteen clinical trials including over 7000 patients. The researchers then analyzed the trial results, systematically logging patient benefits and side effects for different doses of the three main anti-TNF± drugs.

Analysis of the combined results of all thirteen trials showed that anti-TNF± drugs, given at recommended doses, were better than the usual treatments, such as methotrexate, for treating RA. Patients who had previously seen little benefit from methotrexate alone showed a better response with combined anti-TNF± plus methotrexate therapy.

The team found that all three drugs were very similar in their benefits even at doses higher than those recommended by the drug manufacturer. This class of drugs, while very effective, does have a higher frequency of adverse side-effects. Patients on infliximab were most likely to drop out of a trial because of these side effects. In contrast, patients using etanercept had the lowest withdrawal rate. The researchers point out that this could be because this drug was not reported as being used at higher than recommended dosage in the trials.

"Anti-TNF± drugs such as infliximab, adalimumab and etanercept all appear to be effective in the treatment of RA" said Alonso-Ruiz. "Performing comparisons of new drugs is vital for measuring safety/efficacy relationships and monitoring adverse side-effects."

Journal reference: Tumor necrosis factor drugs in rheumatoid arthritis: systematic review and meta-analysis of efficacy and safety. Alberto Alonso-Ruiz, Jose Ignacio Pijoan, Eukene Ansuategui, Arantxa Urkaregi, Marcelo Calabozo and Antonio Quintana. BMC Musculoskeletal Disorders (in press)

 


Story Source:

The above story is based on materials provided by BMC Musculoskeletal Disorders. Note: Materials may be edited for content and length.


Cite This Page:

BMC Musculoskeletal Disorders. "New Rheumatoid Arthritis Drugs Work Better Than Standard Anti-inflammatories, Study Suggests." ScienceDaily. ScienceDaily, 28 April 2008. <www.sciencedaily.com/releases/2008/04/080417084026.htm>.
BMC Musculoskeletal Disorders. (2008, April 28). New Rheumatoid Arthritis Drugs Work Better Than Standard Anti-inflammatories, Study Suggests. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2008/04/080417084026.htm
BMC Musculoskeletal Disorders. "New Rheumatoid Arthritis Drugs Work Better Than Standard Anti-inflammatories, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/04/080417084026.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) — A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) — The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) — A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
How Mt. Everest Helped Scientists Research Diabetes

How Mt. Everest Helped Scientists Research Diabetes

Newsy (Apr. 15, 2014) — British researchers were able to use Mount Everest's low altitudes to study insulin resistance. They hope to find ways to treat diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins